Impact of previous statin use on first intracerebral hemorrhage in cerebral amyloid angiopathy.


Journal

Revue neurologique
ISSN: 0035-3787
Titre abrégé: Rev Neurol (Paris)
Pays: France
ID NLM: 2984779R

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 23 10 2022
revised: 29 01 2023
accepted: 25 02 2023
medline: 5 12 2023
pubmed: 20 8 2023
entrez: 19 8 2023
Statut: ppublish

Résumé

Statins have been associated with an increased risk of spontaneous intracerebral hemorrhage (ICH), but without dedicated study in cerebral amyloid angiopathy (CAA). We aimed to evaluate the association between previous statin treatment and radiological hemorrhagic lesions in a CAA population during a first lobar ICH event. We retrospectively included all patients meeting the modified Boston criteria for probable CAA and admitted for a first lobar ICH between 2010 and 2021 at Rouen University Hospital. Patients were classified as having previous statin treatment or not. We compared the ICH volume, the number of associated cerebral microbleeds (CMBs), and cortical superficial siderosis (CSS) according to previous statin treatment or not. We also compared functional outcomes and ICH recurrence during the follow-up period between the two groups. We included 99 patients, 27 of whom had statin treatment prior to their ICH. The ICH volume and the number of CMBs did not differ between groups. Disseminated CSS was initially more frequent in the statin group (88% versus 57%; P=0.019), but this was no longer significant after adjustment for antiplatelet treatment (P=0.13). The long-term outcome was similar between the two groups with no increased risk of ICH recurrence in the statin-treated group (29.63% versus 23.61%, P=0.54). Previous statin treatment was not associated with more severe hemorrhagic lesions in CAA in terms of ICH volume or number of microbleeds, but a trend for increased disseminated CSS was highlighted, which will require further larger studies.

Identifiants

pubmed: 37598087
pii: S0035-3787(23)00999-2
doi: 10.1016/j.neurol.2023.02.071
pii:
doi:

Substances chimiques

Hydroxymethylglutaryl-CoA Reductase Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1074-1080

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Auteurs

C Helven (C)

Department of Neurology, Rouen University Hospital, 76000 Rouen, France. Electronic address: camille.helven@chu-rouen.fr.

J Burel (J)

Department of Radiology, Rouen University Hospital, 76000 Rouen, France.

M Vannier (M)

Department of Biostatistics, University of Rouen, Rouen University Hospital, 76000 Rouen, France.

D Maltête (D)

Department of Neurology, Rouen University Hospital, 76000 Rouen, France.

O Ozkul-Wermester (O)

Department of Neurology, Rouen University Hospital, 76000 Rouen, France.

C Hermary (C)

Department of Radiology, Rouen University Hospital, 76000 Rouen, France.

D Wallon (D)

Department of Neurology, Rouen University Hospital, 76000 Rouen, France; Inserm U1245, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Department of Neurology, CHU of Rouen, University of Rouen Normandie, 76000 Rouen, France.

L Grangeon (L)

Department of Neurology, Rouen University Hospital, 76000 Rouen, France; Inserm U1245, CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Department of Neurology, CHU of Rouen, University of Rouen Normandie, 76000 Rouen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH